A clinical perspective argues that dual incretin receptor agonists could serve as adjunctive therapy to improve glycemic control, promote weight loss, and reduce insulin requirements in people with type 1 diabetes who also have obesity. The article frames the approach as a potential way to target insulin resistance and metabolic comorbidity in a patient group where classic GLP-1 receptor agonist strategies may not be optimized. It also emphasizes that safety and dosing design will be critical in a physiology where endogenous insulin production is limited. For companies exploring incretin combinations, the piece provides an actionable direction for trial design discussions—especially around endpoints that capture weight, insulin dose, and metabolic markers alongside standard diabetes outcomes.
Get the Daily Brief